Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin

Georgios Chamilos, Aristotle Bamias, Eleni Efstathiou, Pagona M. Zorzou, Efstathios Kastritis, Evagelos Kostis, Christos Papadimitriou, Meletios A. Dimopoulos

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

BACKGROUND. Oral-based antibiotic therapy is the standard of care in the management of cancer patients with low-risk neutropenic fever. Nevertheless, to the authors' knowledge, the best antibiotic regimen and the feasibility of ambulatory treatment have not been clearly defined. METHODS. The authors evaluated the efficacy and safety of moxifloxacin as outpatient treatment in cancer patients with febrile neutropenia who were selected according to the recently proposed Multinational Association for Supportive Care in Cancer (MASCC) risk assessment model. Moxifloxacin was given at a dose of 400 mg orally once daily. RESULTS. Fifty-four patients with solid and hematologic malignancies, the majority of whom (84%) had advanced disease, were included in the current study. The median neutrophil count at the time of study entry was 340/mm3 (range, 20-950/mm3) and the median duration of neutropenia was 4 days (range, 3-14 days). Of 55 neutropenic episodes, 50 (91%) had a successful outcome with a median time to defervescence of 2 days (range, 1-5 days). A multivariate analysis indicated that severe neutropenia (an absolute neutrophil count of < 100 mm3) was the only independent factor associated with treatment failure (P < 0.04). Moxifloxacin was found to be well tolerated and there were no infectious deaths reported. CONCLUSIONS. The results of the current study demonstrated that moxifloxacin was a highly effective and safe regimen in the outpatient treatment of cancer patients with febrile neutropenia.

Original languageEnglish (US)
Pages (from-to)2629-2635
Number of pages7
JournalCancer
Volume103
Issue number12
DOIs
StatePublished - Jun 15 2005

Fingerprint

Fever
Outpatients
Febrile Neutropenia
Neutropenia
Neoplasms
Neutrophils
Anti-Bacterial Agents
Time and Motion Studies
Hematologic Neoplasms
Therapeutics
Standard of Care
Treatment Failure
Multivariate Analysis
Safety
moxifloxacin

Keywords

  • Cancer
  • Moxifloxacin
  • Neutropenic fever
  • Outpatient

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chamilos, G., Bamias, A., Efstathiou, E., Zorzou, P. M., Kastritis, E., Kostis, E., ... Dimopoulos, M. A. (2005). Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer, 103(12), 2629-2635. https://doi.org/10.1002/cncr.21089

Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. / Chamilos, Georgios; Bamias, Aristotle; Efstathiou, Eleni; Zorzou, Pagona M.; Kastritis, Efstathios; Kostis, Evagelos; Papadimitriou, Christos; Dimopoulos, Meletios A.

In: Cancer, Vol. 103, No. 12, 15.06.2005, p. 2629-2635.

Research output: Contribution to journalArticle

Chamilos, G, Bamias, A, Efstathiou, E, Zorzou, PM, Kastritis, E, Kostis, E, Papadimitriou, C & Dimopoulos, MA 2005, 'Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin', Cancer, vol. 103, no. 12, pp. 2629-2635. https://doi.org/10.1002/cncr.21089
Chamilos, Georgios ; Bamias, Aristotle ; Efstathiou, Eleni ; Zorzou, Pagona M. ; Kastritis, Efstathios ; Kostis, Evagelos ; Papadimitriou, Christos ; Dimopoulos, Meletios A. / Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. In: Cancer. 2005 ; Vol. 103, No. 12. pp. 2629-2635.
@article{03ae9d28fc534120ae09a90c73258f14,
title = "Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin",
abstract = "BACKGROUND. Oral-based antibiotic therapy is the standard of care in the management of cancer patients with low-risk neutropenic fever. Nevertheless, to the authors' knowledge, the best antibiotic regimen and the feasibility of ambulatory treatment have not been clearly defined. METHODS. The authors evaluated the efficacy and safety of moxifloxacin as outpatient treatment in cancer patients with febrile neutropenia who were selected according to the recently proposed Multinational Association for Supportive Care in Cancer (MASCC) risk assessment model. Moxifloxacin was given at a dose of 400 mg orally once daily. RESULTS. Fifty-four patients with solid and hematologic malignancies, the majority of whom (84{\%}) had advanced disease, were included in the current study. The median neutrophil count at the time of study entry was 340/mm3 (range, 20-950/mm3) and the median duration of neutropenia was 4 days (range, 3-14 days). Of 55 neutropenic episodes, 50 (91{\%}) had a successful outcome with a median time to defervescence of 2 days (range, 1-5 days). A multivariate analysis indicated that severe neutropenia (an absolute neutrophil count of < 100 mm3) was the only independent factor associated with treatment failure (P < 0.04). Moxifloxacin was found to be well tolerated and there were no infectious deaths reported. CONCLUSIONS. The results of the current study demonstrated that moxifloxacin was a highly effective and safe regimen in the outpatient treatment of cancer patients with febrile neutropenia.",
keywords = "Cancer, Moxifloxacin, Neutropenic fever, Outpatient",
author = "Georgios Chamilos and Aristotle Bamias and Eleni Efstathiou and Zorzou, {Pagona M.} and Efstathios Kastritis and Evagelos Kostis and Christos Papadimitriou and Dimopoulos, {Meletios A.}",
year = "2005",
month = "6",
day = "15",
doi = "10.1002/cncr.21089",
language = "English (US)",
volume = "103",
pages = "2629--2635",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin

AU - Chamilos, Georgios

AU - Bamias, Aristotle

AU - Efstathiou, Eleni

AU - Zorzou, Pagona M.

AU - Kastritis, Efstathios

AU - Kostis, Evagelos

AU - Papadimitriou, Christos

AU - Dimopoulos, Meletios A.

PY - 2005/6/15

Y1 - 2005/6/15

N2 - BACKGROUND. Oral-based antibiotic therapy is the standard of care in the management of cancer patients with low-risk neutropenic fever. Nevertheless, to the authors' knowledge, the best antibiotic regimen and the feasibility of ambulatory treatment have not been clearly defined. METHODS. The authors evaluated the efficacy and safety of moxifloxacin as outpatient treatment in cancer patients with febrile neutropenia who were selected according to the recently proposed Multinational Association for Supportive Care in Cancer (MASCC) risk assessment model. Moxifloxacin was given at a dose of 400 mg orally once daily. RESULTS. Fifty-four patients with solid and hematologic malignancies, the majority of whom (84%) had advanced disease, were included in the current study. The median neutrophil count at the time of study entry was 340/mm3 (range, 20-950/mm3) and the median duration of neutropenia was 4 days (range, 3-14 days). Of 55 neutropenic episodes, 50 (91%) had a successful outcome with a median time to defervescence of 2 days (range, 1-5 days). A multivariate analysis indicated that severe neutropenia (an absolute neutrophil count of < 100 mm3) was the only independent factor associated with treatment failure (P < 0.04). Moxifloxacin was found to be well tolerated and there were no infectious deaths reported. CONCLUSIONS. The results of the current study demonstrated that moxifloxacin was a highly effective and safe regimen in the outpatient treatment of cancer patients with febrile neutropenia.

AB - BACKGROUND. Oral-based antibiotic therapy is the standard of care in the management of cancer patients with low-risk neutropenic fever. Nevertheless, to the authors' knowledge, the best antibiotic regimen and the feasibility of ambulatory treatment have not been clearly defined. METHODS. The authors evaluated the efficacy and safety of moxifloxacin as outpatient treatment in cancer patients with febrile neutropenia who were selected according to the recently proposed Multinational Association for Supportive Care in Cancer (MASCC) risk assessment model. Moxifloxacin was given at a dose of 400 mg orally once daily. RESULTS. Fifty-four patients with solid and hematologic malignancies, the majority of whom (84%) had advanced disease, were included in the current study. The median neutrophil count at the time of study entry was 340/mm3 (range, 20-950/mm3) and the median duration of neutropenia was 4 days (range, 3-14 days). Of 55 neutropenic episodes, 50 (91%) had a successful outcome with a median time to defervescence of 2 days (range, 1-5 days). A multivariate analysis indicated that severe neutropenia (an absolute neutrophil count of < 100 mm3) was the only independent factor associated with treatment failure (P < 0.04). Moxifloxacin was found to be well tolerated and there were no infectious deaths reported. CONCLUSIONS. The results of the current study demonstrated that moxifloxacin was a highly effective and safe regimen in the outpatient treatment of cancer patients with febrile neutropenia.

KW - Cancer

KW - Moxifloxacin

KW - Neutropenic fever

KW - Outpatient

UR - http://www.scopus.com/inward/record.url?scp=20444400553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444400553&partnerID=8YFLogxK

U2 - 10.1002/cncr.21089

DO - 10.1002/cncr.21089

M3 - Article

C2 - 15856427

AN - SCOPUS:20444400553

VL - 103

SP - 2629

EP - 2635

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -